WO2006107902A3 - Use of spirostenols to treat mitochondrial disorders - Google Patents

Use of spirostenols to treat mitochondrial disorders Download PDF

Info

Publication number
WO2006107902A3
WO2006107902A3 PCT/US2006/012380 US2006012380W WO2006107902A3 WO 2006107902 A3 WO2006107902 A3 WO 2006107902A3 US 2006012380 W US2006012380 W US 2006012380W WO 2006107902 A3 WO2006107902 A3 WO 2006107902A3
Authority
WO
WIPO (PCT)
Prior art keywords
spirostenols
mitochondrial disorders
treat mitochondrial
disease
treat
Prior art date
Application number
PCT/US2006/012380
Other languages
French (fr)
Other versions
WO2006107902A9 (en
WO2006107902A8 (en
WO2006107902A2 (en
Inventor
Laurent Lecanu
Laurent Tillement
Vassilios Papadopoulos
Wenguo Yao
Janet Greeson
Original Assignee
Samaritan Pharmaceuticals Inc
Univ Georgetown
Laurent Lecanu
Laurent Tillement
Vassilios Papadopoulos
Wenguo Yao
Janet Greeson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samaritan Pharmaceuticals Inc, Univ Georgetown, Laurent Lecanu, Laurent Tillement, Vassilios Papadopoulos, Wenguo Yao, Janet Greeson filed Critical Samaritan Pharmaceuticals Inc
Priority to EP06740438A priority Critical patent/EP1893219A2/en
Priority to CA002603127A priority patent/CA2603127A1/en
Priority to AU2006231451A priority patent/AU2006231451A1/en
Priority to JP2008504515A priority patent/JP2008534623A/en
Publication of WO2006107902A2 publication Critical patent/WO2006107902A2/en
Publication of WO2006107902A3 publication Critical patent/WO2006107902A3/en
Publication of WO2006107902A9 publication Critical patent/WO2006107902A9/en
Publication of WO2006107902A8 publication Critical patent/WO2006107902A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

The present invention relates to methods and compositions involving the use of spirostenol derivatives for treating, preventing or reducing the risk of developing a mitochondrial disorder or disease or the symptoms associated with a mitochondrial disorder or disease.
PCT/US2006/012380 2005-04-01 2006-03-31 Use of spirostenols to treat mitochondrial disorders WO2006107902A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP06740438A EP1893219A2 (en) 2005-04-01 2006-03-31 Use of spirostenols to treat mitochondrial disorders
CA002603127A CA2603127A1 (en) 2005-04-01 2006-03-31 Use of spirostenols to treat mitochondrial disorders
AU2006231451A AU2006231451A1 (en) 2005-04-01 2006-03-31 Use of spirostenols to treat mitochondrial disorders
JP2008504515A JP2008534623A (en) 2005-04-01 2006-03-31 Use of spirostenol for the treatment of mitochondrial disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US66722905P 2005-04-01 2005-04-01
US60/667,229 2005-04-01
US69751805P 2005-07-08 2005-07-08
US60/697,518 2005-07-08

Publications (4)

Publication Number Publication Date
WO2006107902A2 WO2006107902A2 (en) 2006-10-12
WO2006107902A3 true WO2006107902A3 (en) 2006-11-30
WO2006107902A9 WO2006107902A9 (en) 2007-01-18
WO2006107902A8 WO2006107902A8 (en) 2008-01-24

Family

ID=36676082

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012380 WO2006107902A2 (en) 2005-04-01 2006-03-31 Use of spirostenols to treat mitochondrial disorders

Country Status (5)

Country Link
EP (1) EP1893219A2 (en)
JP (1) JP2008534623A (en)
AU (1) AU2006231451A1 (en)
CA (1) CA2603127A1 (en)
WO (1) WO2006107902A2 (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
WO2003022287A1 (en) * 2001-08-24 2003-03-20 Jilin Tianyao Science And Technology Co. Ltd. USE OF 3β-HYDROXY-5-SPIROSTENE AS DRUGS FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES OR CONDITIONS FOR INHIBITION OF TUMORS AND DECREASING OF BLOOD LIPIDS
WO2003077869A2 (en) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Neuroprotective spirostenol pharmaceutical compositions
WO2003086411A1 (en) * 2002-04-15 2003-10-23 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Compounds and preparation methods of carboxylate and monoester succinate derivative of diosgenin
CN1465344A (en) * 2002-06-21 2004-01-07 成都地奥制药集团有限公司 Medicine composition for treating myocardial ischemia, angina pectoris and cardiac infarction
CN1552725A (en) * 2003-11-29 2004-12-08 良 刘 Preparation of solanine sulfurate and its use in medicine
WO2006044665A2 (en) * 2004-10-14 2006-04-27 Georgetown University Neuroprotective spirostenol pharmaceutical compositions

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680289A (en) * 1985-06-05 1987-07-14 Progenics, Inc. Treatment of obesity and diabetes using sapogenins
WO2003022287A1 (en) * 2001-08-24 2003-03-20 Jilin Tianyao Science And Technology Co. Ltd. USE OF 3β-HYDROXY-5-SPIROSTENE AS DRUGS FOR PREVENTION OR TREATMENT OF CARDIOVASCULAR DISEASES OR CONDITIONS FOR INHIBITION OF TUMORS AND DECREASING OF BLOOD LIPIDS
WO2003077869A2 (en) * 2002-03-15 2003-09-25 Samaritan Pharmaceuticals, Inc Neuroprotective spirostenol pharmaceutical compositions
WO2003086411A1 (en) * 2002-04-15 2003-10-23 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Compounds and preparation methods of carboxylate and monoester succinate derivative of diosgenin
CN1465344A (en) * 2002-06-21 2004-01-07 成都地奥制药集团有限公司 Medicine composition for treating myocardial ischemia, angina pectoris and cardiac infarction
CN1552725A (en) * 2003-11-29 2004-12-08 良 刘 Preparation of solanine sulfurate and its use in medicine
WO2006044665A2 (en) * 2004-10-14 2006-04-27 Georgetown University Neuroprotective spirostenol pharmaceutical compositions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LIU, ZHONGRONG ET AL: "Preparation of carboxylate and monoester succinate derivatives of diosgenin and their bioactivities for treating and preventing cerebrovascular and cardiovascular diseases", XP002391897, retrieved from STN Database accession no. 2003:836864 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; WANG, BENXIANG ET AL: "Use of 3.beta.-hydroxy-5-spirostene as drugs for prevention or treatment of cardiovascular diseases or conditions for inhibition of tumors and decreasing of blood lipids", XP002391898, retrieved from STN Database accession no. 2003:221522 *
DATABASE WPI Section Ch Week 200423, Derwent World Patents Index; Class B04, AN 2004-239758, XP002391987 *
DATABASE WPI Section Ch Week 200524, Derwent World Patents Index; Class B01, AN 2005-223733, XP002391988 *
ROTIG A ET AL: "Molecular diagnostics of mitochondrial disorders", BIOCHIMICA ET BIOPHYSICA ACTA. BIOENERGETICS, AMSTERDAM, NL, vol. 1659, no. 2-3, 6 December 2004 (2004-12-06), pages 129 - 135, XP004679167, ISSN: 0005-2728 *
TILLEMENT LAURENT ET AL: "The spirostenol (22R, 25R)-20alpha-spirost-5-en-3beta-yl hexanoate blocks mitochondrial uptake of Abeta in neuronal cells and prevents Abeta-induced impairment of mitochondrial function.", STEROIDS. AUG 2006, vol. 71, no. 8, August 2006 (2006-08-01), pages 725 - 735, XP002391896, ISSN: 0039-128X *
ZEVIANI MASSIMO ET AL: "Mitochondrial disorders.", BRAIN : A JOURNAL OF NEUROLOGY. OCT 2004, vol. 127, no. Pt 10, October 2004 (2004-10-01), pages 2153 - 2172, XP009069981, ISSN: 1460-2156 *

Also Published As

Publication number Publication date
WO2006107902A9 (en) 2007-01-18
JP2008534623A (en) 2008-08-28
WO2006107902A8 (en) 2008-01-24
WO2006107902A2 (en) 2006-10-12
CA2603127A1 (en) 2006-10-12
EP1893219A2 (en) 2008-03-05
AU2006231451A1 (en) 2006-10-12

Similar Documents

Publication Publication Date Title
WO2008021210A3 (en) Methods and compositions for the treatment of neurodegenerative disorders
WO2009036175A3 (en) F1f0-atpase inhibitors and related methods
WO2007127505A3 (en) Use of sulfonamide derivatives in the treatment of disorders of the metabolism and the nervous system
WO2007075592A3 (en) Materials and methods for treating chronic fibrotic disease
WO2006120176A3 (en) Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
WO2006003388A8 (en) Compositions and methods for treating inflammatory disorders
BRPI0506970B8 (en) alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
WO2007103373A3 (en) Compositions and methods for the treatment of immunoinflammatory disorders
WO2006083533A3 (en) Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
WO2006113242A3 (en) Method of increasing testosterone and related steroid concentrations in women
IL193080A0 (en) Methods, compositions, and kits for the treatment of musculoskeletal disorders and symptoms associated therewith
WO2008016659A3 (en) Agents for treating neurodegenerative diseases
WO2005086656A3 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2012149478A3 (en) Agents useful for treating friedreich's ataxia and other neurodegenerative diseases
WO2007009120A3 (en) Heterotetracyclic compounds as tpo mimetics
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2010030891A3 (en) Aryl guanidine f1f0-atpase inhibitors and related methods
WO2008150530A3 (en) Cripto binding molecules
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel
WO2007022269A3 (en) Compounds and compositions as tpo mimetics
WO2007016338A3 (en) Use of chk2 kinase inhibitors for cancer treatment
WO2008033440A3 (en) Treatment of hyperproliferative diseases with anthraquinones
EP1879591B8 (en) Use of azapaullones for preventing and treating pancreatic autoimmune disorders
WO2007136741A3 (en) N-desmethyl-doxepin and methods of using the same to treat sleep disorders
WO2007144057A3 (en) Antimicrobial carbon

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680018809.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2603127

Country of ref document: CA

Ref document number: 2008504515

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006231451

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006231451

Country of ref document: AU

Date of ref document: 20060331

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2006740438

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU